Top 15 Life Science Startup Investors in Norway in September 2025
A list of 15 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Norway. We rank investors based on the number of investments they made in Life science companies from Norway. We update this investor list every month.Top 15 Life Science Startup Investors in Norway in September 2025
Investor | Life Science Norway investments |
---|---|
Investinor | 3 |
Canica | 2 |
Sandwater | 2 |
ERM Invest | 1 |
Sofinnova Partners | 1 |
Project Sandwater | 1 |
Birk Venture | 1 |
Bakken & Baeck | 1 |
SINTEF Venture AS | 1 |
Dynamk Capital | 1 |
World Wildlife Fund | 1 |
The Index Project | 1 |
Nordic Impact | 1 |
Hadean Ventures | 1 |
H2O Holding AS | 1 |
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more
Investment focus
- Software, Biotechnology, Manufacturing
- Funding Round, Series A, Seed
- Norway, United States, Sweden
Portfolio highlights
- Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Kongsberg Ferrotech — Kongsberg Ferrotech offers game-changing robotic services for inspection, repair, and maintenance (IRM) of underwater installations
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more
Investment focus
- Beauty, Medical, Biotechnology
- Private Equity, Series A, Series D
- Norway, Denmark, Switzerland
Portfolio highlights
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
- Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
We are Sandwater. Regeneration of our resources. Vitalizing healthcare & education. Improving life through technology.
Show more
Investment focus
- Medical, Health Care, Agriculture
- Series A, Funding Round, Seed
- Norway, Germany, Sweden
Portfolio highlights
- Filics — A scalable transport solution for standardized load carriers with a minimum energy footprint
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
Investment Company
Show more
Investment focus
- Software, Health Care, Life Science
- Pre-Seed
- Norway
Portfolio highlights
- Aurora Analytica — Founded in February 2023 and incorporated in January 2024, Aurora Analytica is a pioneering health technology company dedicated to optimizing the clinical trial lifecycle and accelerating the development of new treatment options. Our AI-powered platform provides strategic insights, site intelligence, and data-driven tools that enable biotech andpharmaceutical companies to design faster, smarter trials. A single platform that brings together essential assessments, the Aurora Suite™ consists of eleven interconnected modules that function collaboratively within a comprehensive analytics environment. Built on over 30 years of industry expertise, Aurora Analytica bridges the gap between innovation and execution—reducing costs, improving accuracy, and ultimately helping bring better therapies to patients, faster.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.
- Galvanize Therapeutics — Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more
Investment focus
- Medical, Consulting, Life Science
- Series A
- Norway, The Netherlands
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Series A, Funding Round
- Norway, United Kingdom
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.
Since 2011, we have built products with some of the most ambitious companies out there. From defining future homes with IKEA to building decentralised platforms with Coinbase.
Show more
Investment focus
- Chemical, Software, Life Science
- Seed, Angel
- Norway
Portfolio highlights
- Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
- Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.
We commercialize technology created by SINTEF's research environments
Show more
Investment focus
- Manufacturing, Software, Energy
- Seed, Funding Round, Pre-Seed
- Norway, United States, United Kingdom
Portfolio highlights
- Nomono — Nomono delivers studio-grade spoken audio with next-gen wireless tools. Record anywhere, auto-enhance with AI, and edit in the cloud - trusted by storytellers
- Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
- Hydrogen Mem-Tech — Hydrogen Mem-Tech aim is to make the green shift happen through our state-of-the-art hydrogen separation technology with carbon capture.
Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Seed, Series B
- United States, Canada, Norway
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
- Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.
Show more
Investment focus
- Seafood, Food Processing, Farming
- Seed, Series A, Funding Round
- Norway, Faroe Islands, United Kingdom
Portfolio highlights
- OCEANIUM — OCEANIUM is a world-leading developer of innovative, functional seaweed ingredients to catalyse the seaweed industry for People Health and Ocean Health.
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
- Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.
Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?
Show more
Investment focus
- Artificial Intelligence, Chemical, SaaS
- Seed, Series A, Series B
- United States, Denmark, Chile
Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.
Show more
Investment focus
- Chemical, Life Science, Visual Search
- Seed
- Norway
Portfolio highlights
- Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.
The funds are backed by leading private and institutional investors.
Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Sweden, Norway, Austria
Portfolio highlights
- SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
Investment
Show more
Investment focus
- Software, Health Care, Life Science
- Pre-Seed
- Norway
Portfolio highlights
- Aurora Analytica — Founded in February 2023 and incorporated in January 2024, Aurora Analytica is a pioneering health technology company dedicated to optimizing the clinical trial lifecycle and accelerating the development of new treatment options. Our AI-powered platform provides strategic insights, site intelligence, and data-driven tools that enable biotech andpharmaceutical companies to design faster, smarter trials. A single platform that brings together essential assessments, the Aurora Suite™ consists of eleven interconnected modules that function collaboratively within a comprehensive analytics environment. Built on over 30 years of industry expertise, Aurora Analytica bridges the gap between innovation and execution—reducing costs, improving accuracy, and ultimately helping bring better therapies to patients, faster.
Investors by industry
Google
Marketplace
Hardware
Energy
Proptech
Health Care
Biotech
Artificial intelligence
Climate
Consumer
Community
Impact
Gaming
FinTech
EdTech
Sustainability
Venture Capital
Big Data
Web3
B2B
Financial Services
Finance
Infrastructure
Education
Photography
Payments
Food and Beverage
Video Games
Organic Food
Retail
Beauty
Publishing
Clean Energy
Real Estate
Manufacturing
Art
Music
Android
Internet
Enterprise Software
eSports
Franchise
Sports
Construction
Digital Media
Email
Medical
Social Network
Wellness
Social Media
Mobile
Legal
Local
Recruiting
Cannabis
Platforms
Fitness
Travel
Mobile Advertising
Social
Automotive
Biotechnology
Crowdfunding
Wine And Spirits
Hospitality
Medical Device
CleanTech
Transportation
Mobile Apps
Enterprise
InsurTech
LGBT
Fashion
Oil and Gas
Sporting Goods
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Software
Restaurants
Social Impact
Celebrity
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Canada
South Korea
Ireland
United States
New Zealand
India
Germany
Australia
Armenia
South Africa
Spain
Japan
Africa
China
Sri Lanka
Singapore
Qatar
Asia
Indonesia
Vietnam
Oceania
LATAM
Middle East
Europe
Saudi Arabia
Brazil
Bulgaria
Belize
Bahrain
Croatia
Georgia
Belarus
Hungary
France
Ghana
Ethiopia
Gibraltar
Liechtenstein
Liberia
Lebanon
Mauritius
Chile
Peru
Norway
Israel
Malaysia
Mexico
Nicaragua
Jersey
Panama
Morocco
Mali
Lithuania
Italy
Philippines
Kuwait
Malta
Egypt
Myanmar
Sierra Leone
El Salvador
Uganda
Venezuela
Sweden
Finland
Slovenia
Poland
Uruguay
Ukraine
Tajikistan
Puerto Rico
Costa Rica
Portugal
Tunisia
Taiwan
Tanzania
Turkey
San Marino
Greece
Senegal
Togo
Uzbekistan
Serbia
Russian Federation
Zambia
Rwanda
Zimbabwe
Barbados
Thailand
Belgium
Dominican Republic
Estonia
Bermuda
Czech Republic
Azerbaijan
Iceland
Nigeria
Bahamas
Namibia
Iraq
Denmark
United Arab Emirates
Jamaica
Honduras
Algeria
Isle of Man
Bolivia
Luxembourg
Hong Kong
Pakistan
Albania
Ecuador
Faroe Islands
Kenya
Grenada
Jordan
Romania
Bangladesh
Argentina
Kazakhstan
Cayman Islands
Cambodia
Oman
Latvia
Cyprus
Austria
Switzerland
Cameroon
Guatemala
Colombia
Seychelles
Marshall Islands
Investors in Norway by industry
Clean Energy
Transportation
Financial Services
Cryptocurrency
Big Data
Payments
Medical
Social Network
Medical Device
Internet
Social Media
Manufacturing
Blockchain
Construction
Software
Enterprise Software
Sports
CleanTech
Travel
EdTech
FinTech
Biotechnology
Consumer
Health Care
Sustainability
Climate
Energy
Proptech
Mobile
Impact
Marketplace
SaaS
Artificial intelligence
Community
Hardware
Gaming
Retail
Fashion
Social
B2B
Web3
Life Science
Publishing
Oil and Gas
Education
Enterprise
Renewable Energy
Music
Food and Beverage
Video Games
Biotech
Finance
Real Estate
Media (entertainment)
Agriculture (agtech)
Machine Learning
Digital Media